Thursday, September 12
12.00 pm
Registration and welcome reception
12.30 pm -
12.50 pm
Welcome Notes and Introduction
12.30 pm
Welcome, Introduction and Objectives
Frank Siebenhaar (Berlin, Germany)
12.40 pm
Status of the ECNM 2024 and Perspectives for the Future
Massimo Triggiani (Salerno, Italy) & Peter Valent (Vienna, Austria)
12.50 pm
Presentation of the Researcher of the Year of the ECNM 2024
Massimo Triggiani (Salerno, Italy) & Peter Valent (Vienna, Austria)
1.00 pm
Lecture of the Researcher of the Year 2024: Development and translation of KIT-targeting treatments in advanced systemic mastocytosis
Andreas Reiter (Mannheim, Germany)
1.30 pm
Coffee break
1.50 pm -
3.10 pm
Session I: Mastocytosis: Updates in Pathology and Classification
Chairs: Karl Sotlar (Salzburg, Austria) & Wolfgang R. Sperr (Vienna, Austria)
1.50 pm
The infinite expanse of pathology: unique and complex patterns in systemic mastocytosis
Hans-Peter Horny (Munich, Germany)
2.10 pm
Histological grading and treatment in advanced and non-advanced systemic mastocytosis
Tracy George (Salt Lake City, USA)
2.30 pm
Histological assessment and prognostication of liver involvement in systemic mastocytosis
Gandhi Damaj (Caen, France)
2.50 pm
Update on the harmonization of ECNM/AIM, WHO and ICC classifications
Peter Valent (Vienna, Austria)
3.10 pm
Coffee break
3.30 pm -
4.50 pm
Session II: Pediatric Mastocytosis and Mastocytosis in the Skin
Chairs: Clive Grattan (London, U.K.) & Karin Hartmann (Basel, Switzerland)
3.30 pm
Current challenges in the diagnosis of pediatric mastocytosis
Magdalena Lange (Gdansk, Poland)
3.50 pm
Systemic involvement in pediatric mastocytosis: how mattern is the pattern?
Melody Carter (Bethesda, USA)
4.10 pm
Systemic mastocytosis in children - an emerging problem or underestimated disease?
Joanna Renke (Gdansk, Poland)
4.30 pm
Challenges in the diagnosis of cutaneous mastocytosis in adolescents and adults
Knut Brockow (Munich, Germany)
4.50 pm
Coffee break
5.20 pm -
6.20 pm
Session III: Comorbidities in Mastocytosis
Chairs: Gunnar Nilsson (Uppsala, Sweden) & Sigurd Broesby-Olsen (Odense, Denmark)
5.20 pm
Characteristics of osteoporosis caused by systemic mastocytosis
Heide Siggelkow (Göttingen, Germany)
5.40 pm
Prevalence of bone manifestations in different subtypes of mastocytosis
Cristina B. Livideanu (Toulouse, France)
6.00 pm
Epidemiology of mastocytosis: a population-based study (Sweden)
Anna Bergström (Uppsala, Sweden)
6.20 pm -
6.50 pm
Keynote Lecture I
Introduction: Martin Metz (Berlin, Germany)
6.20 pm
Understanding the physiology of mast cells: how they benefit us
Stephen J. Galli (Stanford, USA)
6.50 pm
Summary of Day 1 and Announcements
7.30 - 10.00 pm
Supporting Programme
Baret on top of the Humboldt Forum
Friday, 13 September 2024
8.30 am
Welcome Coffee
8.45 am
Welcome and Introduction
Frank Siebenhaar (Berlin, Germany) & Peter Valent (Vienna, Austria)
9.00 am -
10:00 am
Session IV: ECNM Registry Projects Part I
Chairs: Michel Arock (Paris, France) & Wolfgang R. Sperr (Vienna, Austria)
9.00 am
Overview of projects of the ECNM registry
Wolfgang R. Sperr (Vienna, Austria)
9.20 am
Summary of status and overview of first, second, and third wave projects
Massimo Triggiani (Salerno, Italy) & Peter Valent (Vienna, Austria)
9.30 am
Pediatric Mastocytosis: Clinical Features and Course (PR29)
Magdalena Lange & Marek Niedoszytko (Gdansk, Poland)
9.40 am
Prognostic Impact of Monocytosis in Mastocytosis (PR30)
Nikolas von Bubnoff & Friederike Wortmann (Lübeck, Germany)
9.50 am
Evaluation of Inflammation Parameters in Mastocytosis (PR31)
Christos Fokoloros (Athens, Greece)
10.00 am
Coffee Break
10.20 am -
11:30 am
Session IV: ECNM Registry Projects Part II
Chairs: Michel Arock (Paris, France) & Wolfgang R. Sperr (Vienna, Austria)
10.20 am
Impact of region and referral site type in Mastocytosis (PR32)
Knut Brockow (Munich, Germany)
10.30 am
Impact of CD2, CD25 and CD30 expression on MC in systemic mastocytosis (PR36)
Axel Rüfer (Luzern, Switzerland)
10.40 am
Efficacy and safety of mammalian target of rapamycin inhibitors in systemic mastocytosis: a nationwide French pilot study
Olivier Hermine (Paris, France)
10.50 am
Evaluation of the impact of specific allergies in mastocytosis (PR38)
Hanneke Oude Elberink (Groningen, The Netherlands)
11.00 am
Prognostic impact of the 2022-updated WHO and ICC classifications (PR40)
Roberta Zanotti (Verona, Italy)
11.10 am
Clinical impact of vitamin D levels in mastocytosis (PR41)
Ingunn Dybedal (Oslo, Norway)
11.20 am
Additional and new registry projects, summary, and discussion
Peter Valent (Vienna, Austria) & ECNM Registry Group
11.30 am - 12.30 pm
Closed ECNM Registry Steering Committee Meeting
11.30 am - 1.00 pm
Lunch Break
1.00 pm -
1:30 pm
Keynote Lecure II
Introduction: Frank Siebenhaar (Berlin, Germany)
1.00 pm
Is inhibitory receptor activation on transformed mast cells useful in fighting mastocytosis?
Francesca Levi-Schaffer (Jerusalem, Israel)
1.30 pm -
2:30 pm
Session V: Translational and Real World Research in Mastocytosis
Chairs: Mariana C. Castells (Boston, USA) & Marek Niedoszytko (Gdansk, Poland)
1.30 pm
Challenges in the management of mastocytosis: a worldwide survey
Polina Pyatilova (Berlin, Germany)
1.50 pm
Symptom distribution, quality of life and disease control in patients with mastocytosis
Frank Siebenhaar (Berlin, Germany)
2.10 pm
How not to miss mastocytosis among patients with anaphylaxis
Sigurd Broesby-Olsen (Odense, Denmark)
2.30 pm
Coffee Break
3.00 pm -
4:40 pm
Session VI: Clinical Phenotypes in Mastocytosis and Related Disorders
Polina Pyatilova (Berlin, Germany) & Massimo Triggiani (Salerno, Italy)
3.00 pm
Predictors of clonality and underlying mastocytosis in mast cell activation syndromes
Ivan Álvarez-Twose (Toledo, Spain)
3.20 pm
Clinical, morphological and molecular pattern of gastrointestinal involvement in systemic mastocytosis
Johannes Lübke (Mannheim, Germany)
3.40 pm
The influence of nutritional habits, body mass index and intestinal microbiota in mastocytosis
Ewelina Harcęko-Zielińska (Gdansk, Poland)
4.00 pm
Impact of hereditary alpha-tryptasemia on disease phenotypes in mastocytosis
Lawrence B. Schwartz (Richmond, USA)
4.20 pm
Clinical perspectives of hereditary alpha-tryptasemia (PR44)
Nikolas von Bubnoff (Lübeck, Germany)
4.40 pm
Coffee Break
5.10 pm -
6:55 pm
Session VII: Molecular Pattern, Precision Medicine, and Prognostication in Mastocytosis
Chairs: Alberto Orfao (Salamanca, Spain) & Andreas Reiter (Mannheim, Germany)
5.10 pm
KIT mutations and other genetic defects in mastocytosis: Implications for disease pathology and targeted therapies
Michel Arock (Paris, France)
5.25 pm
Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
Juliana Schwaab (Mannheim, Germany)
5.40 pm
TNF promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of surviving and impact on prognosis
Georg Greiner (Vienna, Austria)
5.55 pm
Novel preclinical mouse models to investigate downstream signaling and potential treatment options in mastocytosis
Martina Konantz (Basel, Schweiz)
6.10 pm
Analysis of the kinome from patients with cutaneous mastocytosis
Dagmar von Bubnoff (Lübeck, Germany)
6.25 pm
Genome-wide DNA methylation and gene expression profiles in patients with indolent systemic mastocytosis
Aleksandra Gorska (Gdansk, Poland) & Marek Niedoszytko (Gdansk, Poland)
6.40 pm
Poor applicability of currently available prognostic scoring systems for prediction of outcome in KIT D816V-negative advanced systemic mastocytosis
Juliana Schwaab (Mannheim, Germany)
6.55 pm
Summary of Day 2 and Announcements
7.30 -
10.00 pm
10.00 pm
Supporting programme
Telegraphenamt
Saturday, 14 September 2024
8.00 am
Welcome Coffee
8.15 am -
9.45 am
Session VIII: Anaphylaxis and Mast Cell Activation Syndrome
Chairs: Francesca Norelli (Verona, Italy) & Vito Sabato (Antwerp, Belgium)
8.15 am
Diagnostic criteria and updated classification of MCAS and other MCAD
Peter Valent (Vienna, Austria)
8.30 am
Role of mastocytosis in anaphylaxis: data from the European anaphylaxis registry
Veronika Höfer (Berlin, Germany)
8.45 am
Drug-induced anaphylaxis in mastocytosis: findings from large cohorts
Michiel Beyens (Antwerp, Belgium)
9.00 am
Challenges in drug and hymenoptera venom hypersensitivity diagnosis and management in mastocytosis
Mariana C. Castells (Boston, USA)
9.15 am
Diagnostic work up and management of anaphylaxis in mastocytosis
Hanneke Oude Elberink (Groningen, The Netherlands)
9.30 am
Prevalence, diagnosis, and management of MCAS: an update
Theo Gülen (Stockholm, Sweden)
9.45 am
Coffee Break
10.05 am -
12.00 pm
Session IX: Treatment Aims, Targeted Treatment and Unmet Needs in Advanced and Non-Advanced systemic mastocytosis
Chairs: Deepti Radia (London, U.K.) & Juliana Schwaab (Mannheim, Germany)
10.05 am
Best supportive care for the treatment of mast cell mediator-related symptoms in mastocytosis
Massimo Triggiani (Salerno, Italy)
10.25 am
Update on targeted treatment for non-advanced systemic mastocytosis
Karin Hartmann (Basel, Switzerland)
10.45 am
Update on targeted treatment for advanced systemic mastocytosis
Jason Gotlib (Stanford, USA)
11.05 am
Altered immune profiles and ultra-sensitive blood assays in the diagnostic work-up of systemic mastocytosis
Alberto Orfao (Salamanca, Spain)
11.25 am
Aims, needs, and future perspectives in the treatment of non-advanced systemic mastocytosis
Vito Sabato (Antwerp, Belgium)
11.45 am
Development of a mast cell depleting antibody for the treatment of mastocytosis
William Worrall (Toulouse, France)
12.00 pm
Lunch Break
12.50 pm -
2.35 pm
Session X: Late Breaking Updates
Chairs: Knut Brockow (Munich, Germany) & Lawrence B. Schwartz (Richmond, USA)
12.50 pm
Allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a retrospective analysis of the DRST and GREM registries
Jens Panse (Aachen, Germany)
1.05 pm
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: best practice recommendations
Deepti Radia (London, U.K.)
1.20 pm
Allo-HSCT in advanced systemic mastocytosis: the Vienna experience
Karoline V. Gleixner (Vienna, Austria)
1.35 pm
Cladribine improves cutaneous manifestations and quality of life of patients with mastocytosis
Stéphane Barete (Paris, France)
1.50 pm
CRISPR/Cas engineered iPSCs: a novel cell-based model for mastocytosis
Yanyan Luo (Berlin, Germany)
2.05 pm
The synthetic triterpenoids bardoxolone methyl and omaveloxolone synergize with KITD816V-targeting drugs in counteracting the survival of neoplastic cells in advanced systemic mastocytosis
Max V. John (Vienna, Austria)
2.20 pm
Advancements in highly sensitive detection of KIT D816V mutation in blood: transforming diagnostic practices for systemic mastocytosis
Rudi Steffensen (Aalborg, Denmark)
2.35 pm
Summary of Day 3 and Closing Remarks
3.00 pm -
4.00 pm
Hybrid Session with online stream open for registered patients
3.00 pm
Post-ECNM Meeting and Round Table Discussion
3.00 pm
Summary and Highlights of ECNM 2024
Karin Hartmann & Jens Panse
3.15 pm
Round Table Discussion
Panelists: Knut Brockow, Melody Carter, Mariana C. Castells, Karin Hartmann, Jens Panse, Vito Sabato; Moderator: Frank Siebenhaar
3.55 pm